{"id":"mycoster-r","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for this investigational formulation are limited in public literature, Mycoster appears to be designed as an antifungal therapeutic, likely targeting ergosterol synthesis or cell wall components critical to fungal pathogens. The drug is in phase 3 development, suggesting it has demonstrated sufficient preclinical and early clinical activity to warrant advanced testing.","oneSentence":"Mycoster is an antifungal agent that disrupts fungal cell wall synthesis or membrane integrity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:22.367Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fungal infections (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT02004860","phase":"PHASE3","title":"Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2014-01","conditions":"Severe Seborrheic Dermatitis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":956640,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ciclopirox olamine"],"phase":"phase_3","status":"active","brandName":"Mycoster (R)","genericName":"Mycoster (R)","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycoster (R) is an intervention studied in a clinical trial for the treatment of Severe Seborrheic Dermatitis. The trial, NCT02004860, also compared Mycoster (R) to Protopic (R) in the maintenance treatment of Severe Seborrheic Dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}